# Severe Pertussis During Early Infancy from a High-Altitude Region: Two Clinical Cases and Literature Review

**Authors:** Hongju Chen, Sezhen Baima, Xiaoming Xu, Tao Wang, Jing Shi

PMC · DOI: 10.3390/jcm15062211 · 2026-03-14

## TL;DR

This paper reports two severe pertussis cases in infants from a high-altitude region and discusses how altitude affects disease severity and treatment.

## Contribution

The first high-altitude case series of severe infantile pertussis, revealing altitude-specific risk factors and management strategies.

## Key findings

- High-altitude stressors like hypoxia and hypercoagulability worsen pertussis severity in infants.
- Early non-invasive ventilation and anticoagulation improved outcomes in high-altitude pertussis cases.
- Exchange transfusion was effective in treating extreme leukocytosis in one case.

## Abstract

Objective: To investigate how the high-altitude environment modifies severe pertussis in young infants and analyze its pathophysiological mechanisms and clinical management implications. Methods: Clinical data of two young infants with severe pertussis residing at 3650 m were retrospectively analyzed, including presentation, laboratory findings, pathogen detection, treatment, and outcomes. A literature review explored synergistic interactions between high-altitude factors and pertussis pathophysiology. Results: Case 1 had macrolide-resistant Bordetella pertussis (MRBP, 23S rRNA A2047G) with peak WBC 52.25 × 109/L, and received cefoperazone-sulbactam, piperacillin-tazobactam and azithromycin, and was successfully treated with trimethoprim-sulfamethoxazole combined with exchange transfusion. Case 2 had Bordetella pertussis confirmed by PCR with peak WBC 36.55 × 109/L, receiving cefoperazone-sulbactam and azithromycin, and recovered. Both developed respiratory failure requiring non-invasive ventilation and survived without pulmonary hypertension. High-altitude stressors—hypoxia, enhanced pulmonary vascular reactivity, and hypercoagulability—synergize with pertussis-induced hyperleukocytosis as a “dual hit,” accelerating cardiopulmonary deterioration and elevating thrombotic risks. Conclusions: High altitude is an independent risk modifier in infantile pertussis, demanding heightened vigilance and proactive interventions: early non-invasive ventilation, prophylactic anticoagulation, and timely exchange transfusion before pulmonary hypertension develops. This is the first high-altitude case series that provides essential insights for clinicians in similar environments globally, guiding early recognition and proactive management strategies to improve outcomes in this vulnerable population.

## Linked entities

- **Chemicals:** piperacillin-tazobactam (PubChem CID 461573), azithromycin (PubChem CID 447043), trimethoprim-sulfamethoxazole (PubChem CID 358641)
- **Diseases:** pertussis (MONDO:0005077), respiratory failure (MONDO:0021113), pulmonary hypertension (MONDO:0005149)

## Full-text entities

- **Diseases:** thrombotic (MESH:D013927), cardiopulmonary deterioration (MESH:D006323), Pertussis (MESH:D014917), respiratory failure (MESH:D012131), pulmonary hypertension (MESH:D006976), hypoxia (MESH:D000860)
- **Chemicals:** trimethoprim-sulfamethoxazole (MESH:D015662), piperacillin-tazobactam (MESH:D000077725), azithromycin (MESH:D017963), macrolide (MESH:D018942), cefoperazone-sulbactam (-)
- **Species:** Bordetella pertussis (species) [taxon 520]
- **Mutations:** A2047G

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027209/full.md

---
Source: https://tomesphere.com/paper/PMC13027209